test

Developmental Therapeutics

Roy S. Herbst MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Translational Working Group Leader, Thoracic Oncology Program, Yale Cancer Center

Clinical Interests

Lung cancer; Thoracic Oncology; Personalized Cancer Medicine; Clinical Trials for Lung cancer; Tumor profiling; Tumor biomakers


Board Certifications

1997
Medical Oncology, Board Certified

Patient Care Locations

roy_herbstfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Colon, Lung, and RectumA PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung and Melanoma, skinA Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases

More Clinical Trials...

Edit Profile